1001 related articles for article (PubMed ID: 16678649)
41. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
Brown RT; Perwien A; Faries DE; Kratochvil CJ; Vaughan BS
Clin Pediatr (Phila); 2006 Nov; 45(9):819-27. PubMed ID: 17041169
[TBL] [Abstract][Full Text] [Related]
42. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
[TBL] [Abstract][Full Text] [Related]
43. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
44. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
45. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
46. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
[TBL] [Abstract][Full Text] [Related]
48. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
Wigal T; Brams M; Frick G; Yan B; Madhoo M
Postgrad Med; 2018 Jun; 130(5):481-493. PubMed ID: 29809075
[TBL] [Abstract][Full Text] [Related]
49. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
50. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.
Weisler RH; Biederman J; Spencer TJ; Wilens TE; Faraone SV; Chrisman AK; Read SC; Tulloch SJ
CNS Spectr; 2006 Aug; 11(8):625-39. PubMed ID: 16871129
[TBL] [Abstract][Full Text] [Related]
51. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
Childress AC; Brams M; Cutler AJ; Kollins SH; Northcutt J; Padilla A; Turnbow JM
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
[TBL] [Abstract][Full Text] [Related]
52. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
53. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
54. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Adler LA; Spencer TJ; Williams DW; Moore RJ; Michelson D
J Atten Disord; 2008 Nov; 12(3):248-53. PubMed ID: 18448861
[TBL] [Abstract][Full Text] [Related]
55. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.
Adler L; Dietrich A; Reimherr FW; Taylor LV; Sutton VK; Bakken R; Allen AJ; Kelsey D
Ann Clin Psychiatry; 2006; 18(2):107-13. PubMed ID: 16754416
[TBL] [Abstract][Full Text] [Related]
56. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
57. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
[TBL] [Abstract][Full Text] [Related]
59. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
[TBL] [Abstract][Full Text] [Related]
60. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.
Kahbazi M; Ghoreishi A; Rahiminejad F; Mohammadi MR; Kamalipour A; Akhondzadeh S
Psychiatry Res; 2009 Aug; 168(3):234-7. PubMed ID: 19439364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
